S-1/A: AEON Biopharma Eyes Public Markets: Files Amendment for Stock and Warrant Resale

AEON Biopharma is seeking to register the resale of a substantial number of its common stock and warrants, as well as shares issuable upon exercise of existing warrants and options.

Summary

• AEON Biopharma has filed an amendment to its S-1 registration statement with the SEC.
• The filing covers the potential resale of up to 64,895,022 shares of common stock.
• This includes shares issued in connection with a prior business combination, PIPE subscriptions, and those issuable upon conversion of convertible notes and exercise of stock options.
• The filing also covers the resale of up to 3,988,952 private placement warrants.
• AEON may receive up to approximately $45.9 million from the cash exercise of the Private Placement Warrants.
• The company intends to use any net proceeds from the exercise of such securities for general corporate and working capital purposes.
• The likelihood of warrant exercise is dependent on the trading price of AEON's common stock exceeding $11.50.
• The company acknowledges uncertainties regarding its ability to raise additional capital and its ability to continue as a going concern.
• The company is registering the securities for resale to satisfy registration rights held by certain securityholders.
• The sale of a substantial number of securities could negatively impact the market price of AEON's common stock.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While it highlights the potential of AEON's product and the market opportunity, it also emphasizes significant risks, uncertainties, and financial challenges, including a going concern warning. The overall tone is cautious and concerning from an investment perspective.

Positives

• Registration of securities allows Registered Holders to sell shares.
• Potential for AEON to receive proceeds from warrant exercises, increasing liquidity.

Negatives

• The company's management has concluded that uncertainties around its ability to raise additional capital raise substantial doubt about its ability to continue as a going concern.
• The sale of a substantial number of securities could negatively impact the market price of AEON's common stock and warrants.
• The current trading price of the common stock ($1.44) is significantly below the warrant exercise price ($11.50), making warrant exercise unlikely unless the stock price increases substantially.
• The company acknowledges that it will require additional financing to fund its future operations.

Risks

• The company's management has concluded that uncertainties around its ability to raise additional capital raise substantial doubt about its ability to continue as a going concern.
• The company's future success depends on the successful and timely regulatory approval and commercialization of ABP-450.
• Clinical product development is a lengthy, expensive, and uncertain process.
• Even if ABP-450 receives regulatory approval, it may fail to achieve market acceptance.
• The company relies on a third-party manufacturer, Daewoong, for ABP-450, and any production problems could adversely affect the company.
• Sales of a substantial number of the company's securities in the public market by existing securityholders could cause the price of the company's common stock to fall.

Future Outlook

The company expects to continue to incur losses for the foreseeable future and will need to raise additional capital to fund its operations.

Industry Context

The document highlights the competitive landscape of the pharmaceutical industry, particularly in the botulinum toxin market, with established players like AbbVie (Botox), Ipsen (Dysport), and Merz (Xeomin). It also mentions emerging competitors like Revance Therapeutics. The document also discusses the impact of the Biologics Price Competition and Innovation Act (BPCIA) and the potential for biosimilar competition.

Comparison to Industry Standards

• The document mentions Botox, Dysport, and Xeomin as key competitors in the botulinum toxin market.
• It notes that ABP-450, if approved, will face competition from other pharmaceutical products for the treatment of cervical dystonia, migraine, and gastroparesis.
• The document also references Revance's daxibotulinumtoxinA as a potential competitor with a longer duration of effect.

Legal Proceedings

• Odeon Capital Group LLC filed a lawsuit against the company in the Supreme Court of the State of New York, alleging failure to pay a deferred underwriting fee of $1.25 million.

Related Party Transactions

• Daewoong Pharmaceutical Co., LTD., a beneficial holder of more than 5% of the company's Common Stock, is party to a subscription agreement relating to the sale and issuance of senior secured convertible notes in the principal amount of up to $15.0 million.
• Daewoong Pharmaceutical Co., LTD. is party to a Fourth Amendment to the License Agreement, which amends that certain License and Supply Agreement, by and between the company and Daewoong.
• The Sponsor and certain Priveterra insiders party thereto entered into a sponsor agreement, pursuant to which fifty percent (50)% of the 6,900,000 Founder Shares, or the Contingent Founder Shares, are subject to certain time and performance-based vesting provisions.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings and potential decline in stock price due to sales by existing securityholders.
• Employees: Uncertainty about the company's ability to continue as a going concern could impact job security.
• Customers: Potential impact on the availability of ABP-450 if the company is unable to secure additional funding.
• Suppliers: Potential impact on the company's ability to meet its contractual obligations if it is unable to continue as a going concern.
• Creditors: Increased risk of default if the company is unable to raise additional capital.

Next Steps

• The company will continue to evaluate the complete dataset from its Phase 2 migraine trials and determine the next steps in the development of ABP-450.
• The company is continuing to evaluate other cash preservation measures and will review all strategic options.
• The company is actively attempting to secure additional capital to fund its operations.

Key Dates

Keywords

AEON Biopharma, Registration Statement, Common Stock, Warrants, Resale, ABP-450, Capital Raise, Financial Condition, Risk Factors, Biopharmaceutical